查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046839

患者來源異種移植模型市場－全球產業規模、佔有率、趨勢、機會、預測：按腫瘤類型、類型、最終用戶、地區和競爭格局分類，2021-2031年

Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tumor Type, By Type, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球患者來源異種移植 (PDX) 模型市場預計將從 2025 年的 25.7 億美元大幅成長至 2031 年的 45.6 億美元，複合年成長率為 10.03%。

這些先進的臨床前工具旨在將人類腫瘤組織移植到免疫力缺乏小鼠體內，同時保留原發腫瘤的特徵和微環境。其主要驅動力在於加速向個人化醫療轉型，並提高抗癌藥物研發的成功率。預計到2025年，美國將新增2,041,910例癌症病例，因此迫切需要此類高保真模型來應對日益成長的疾病負擔。個人化醫療和精準腫瘤學的進步正發揮關鍵的催化作用，促使人們更需要能夠精確模擬人類腫瘤生物學的模型，以便有效檢驗生物標記並篩檢候選藥物。 2024 年超過 60 種抗癌藥物的核准進一步佐證了這項需求。與此同時，製藥和生物技術領域強勁的研發投入——包括Astra Zeneca研發預算成長 24%，以及預計到 2025 年美國國家癌症研究所 (NCI) 將獲得 72.2 億美元的聯邦撥款——為擴展這些資源彙整平台以及將患者來源的異質骨移植整合到標準化的藥物發現工作流程中提供了必要的資金。

市場概覽
預測期 2027-2031
市場規模：2025年 25.7億美元
市場規模：2031年 45.6億美元
複合年成長率：2026-2031年 10.03%
成長最快的細分市場 會議
最大的市場 北美洲

市場促進因素

個人化醫療和精準腫瘤學的日益普及是全球患者來源異種移植模型市場的主要驅動力，從根本上改變了臨床前試驗策略。隨著製藥公司優先研發針對特定基因突變的客製化治療方法，與傳統細胞株係不同，能夠精確模擬人類腫瘤生物學的模型需求顯著成長。這些模型對於檢驗生物標記和篩檢候選化合物至關重要，可用於評估其對異質性腫瘤群體的療效，確保新型化合物能夠有效靶向特定的分子特徵。根據美國癌症研究協會 (AACR) 於 2025 年 1 月發表的題為「2024 年 10 月至 12 月 FDA 腫瘤藥物核准」的博報導，監管機構將在 2024 年批准超過 60 項腫瘤相關核准，其中 11 項為First-in-Class療法。如此大量的標靶治療核准凸顯了該行業對 PDX 等預測工具的依賴，這些工具可用於對患者進行分層，並加速新治療方法的臨床應用。同時，製藥和生技領域研發投入的激增為這些資源彙整平台的擴展提供了必要的資金基礎。主要產業參與者正積極增加對藥物研發管線的投資，以降低後期臨床試驗失敗的風險，並優先考慮具有更高轉化有效性的高精度模型。根據Fierce Biotech 2025年3月發布的出版報告《2024年研發預算排名前十的製藥公司》，Astra Zeneca在2024會計年度將研發預算提高了24%，以支持其多元化的腫瘤產品組合。除了企業支出之外，基礎性支援對於維持市場整體穩定仍然至關重要。據美國國家癌症研究所（NCI）稱，該機構在2025年獲得了總合72.2億美元的聯邦資金，用於支持其研究舉措。這些增加的資源將共同促進患者來源異質骨移植（PDX）更廣泛地整合到標準藥物開發流程中。

市場挑戰

儘管市場呈現強勁成長勢頭，但由於開發和維護這些複雜模型成本高且資源密集，市場仍面臨許多挑戰。與標準細胞株係不同，PDX模型需要專門的免疫力缺乏小鼠、先進的動物飼養設施以及持續的技術監管，導致營運成本龐大。這種經濟負擔成為資金緊張的學術研究機構和中小型生物製藥公司進入該領域的主要障礙，常常迫使他們使用更便宜但精度較低的臨床前工具，從而限制了市場滲透率。公共部門支持的波動進一步加劇了這一限制，例如，美國國立衛生研究院（NIH）計劃在2025年削減40%的聯邦撥款，這將限制其購買力，並使成本效益優先於模型的複雜性。儘管如此，塑造市場發展的關鍵趨勢，特別是人源化免疫系統模型的廣泛應用，仍在穩步推進。這些移植了人造血幹細胞或周邊血單核細胞的新一代平台，透過實現腫瘤-免疫系統相互作用和查核點抑制劑療效的精準評估，重新定義了臨床前評估的概念。這推動了產品線的擴展，例如由查爾斯河實驗室（Charles River Laboratories）推出的新型PBMC模型。同時，多組學體學和人工智慧分析的整合，正在將PDX（患者來源模型）的應用從簡單的篩檢轉變為詳細的生物學表徵。透過將基因組、轉錄組和蛋白質組數據與機器學習結合，開發人員現在可以識別預測性生物標記並模擬虛擬對照組。這顯著提高了轉化研究的可靠性，並創造了更盈利的收入來源。這也是Champions Oncology利用其專有的多元組體學資料集服務和人工智慧驅動平台，實現季度收入創紀錄的因素之一。

市場趨勢

隨著研究人員將評估免疫腫瘤療法的臨床前工具列為優先事項，人源化免疫系統模型的廣泛應用正在迅速重塑市場模式。與傳統的免疫力缺乏平台不同，這些新一代模型移植了人造血幹細胞或周邊血單核細胞，從而能夠精確評估腫瘤與免疫系統的相互作用以及查核點抑制劑的療效。這種轉變正推動領先的供應商大幅擴展產品組合，以滿足長期研究的技術需求。在查爾斯河實驗室2025年4月發布的新聞稿《查爾斯河利用先進技術加速腫瘤藥物發現與開發》中，該公司透過推出兩種專門用於延緩移植物抗宿主疾病（GVHD）發生的新型PBMC模型，擴展了其商業產品線。這延長了免疫介導藥物篩檢的治療窗口。同時，多組體學和人工智慧分析的整合正在改變PDX（患者來源腫瘤模型）的應用，使其從簡單的篩檢轉向詳細的生物學表徵。透過將基因組、轉錄組和蛋白質組數據與機器學習演算法結合，開發人員可以識別預測性生物標記並模擬虛擬對照組，從而顯著提高轉化研究的可靠性。隨著製藥客戶需要超越標準腫瘤生長抑制指標的可操作性見解，這種以數據為中心的方法已成為盈利的收入來源。根據 Investing.com 2025 年 3 月發表的一篇報導《Champions Oncology 2025 年第一季業績超出預期》，Champions Oncology 實現了創紀錄的 1700 萬美元季度收入。這項財務里程碑主要歸功於該公司專有的多組體學資料集服務和人工智慧驅動平台的強勁成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：病患來源異種移植模型的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依腫瘤類型（肺癌、胰臟癌、攝護腺癌、乳癌、其他癌症）
    • 依物種（小鼠、大鼠）
    • 按最終使用者（住院機構、社區醫療機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美病患來源異種移植模型的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲病人來源異種移植模型的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區病患來源異種移植模型的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲病患來源異種移植模型的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲病患來源異種移植模型的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球病患來源異種移植模型市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Charles River Laboratories Inc.
  • The Jackson Laboratory
  • Crown Bioscience,Inc.
  • Altogen Labs
  • Envigo RMS LLC
  • WuxiAppTec Co. Ltd
  • Oncodesign Services SA
  • Hera BioLabs Inc.
  • XenTech SAS
  • Abnova Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16332

The Global Patient-Derived Xenograft (PDX) Model Market is projected to expand significantly, from USD 2.57 Billion in 2025 to USD 4.56 Billion by 2031, reflecting a 10.03% CAGR. These advanced preclinical tools, created by implanting human tumor tissue into immunodeficient mice to preserve original tumor characteristics and microenvironment, are primarily propelled by the accelerating shift toward personalized medicine and the critical need to enhance oncology drug development success rates. With 2,041,910 new cancer cases projected in the United States for 2025, the demand for such high-fidelity models to address the growing disease burden is urgent. This push for personalized medicine and precision oncology serves as a key catalyst, intensifying the need for models that accurately mimic human tumor biology for validating biomarkers and screening drug candidates effectively, a necessity underlined by over 60 oncology approvals in 2024. Simultaneously, robust R&D expenditure within pharmaceutical and biotechnology sectors, including a 24% increase in AstraZeneca's research budget and $7.22 billion in federal funding for the National Cancer Institute in 2025, provides the financial infrastructure required to scale these resource-intensive platforms and integrate patient-derived xenografts into standard drug development workflows.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.57 Billion
Market Size 2031USD 4.56 Billion
CAGR 2026-203110.03%
Fastest Growing SegmentMice
Largest MarketNorth America

Market Driver

The increasing adoption of personalized medicine and precision oncology acts as a primary catalyst for the Global Patient-Derived Xenograft Model Market, fundamentally reshaping preclinical testing strategies. As drug developers prioritize therapies tailored to specific genetic mutations, the demand for models that accurately mimic human tumor biology-unlike traditional cell lines-has intensified significantly. These models are now indispensable for validating biomarkers and screening candidates for efficacy against heterogeneous tumor populations, ensuring that new compounds target specific molecular profiles effectively. According to the American Association for Cancer Research, January 2025, in the 'FDA Approvals in Oncology October-December 2024' blog post, regulatory bodies issued more than 60 oncology approvals in 2024, including 11 first-in-class therapeutics. This high volume of targeted regulatory clearances underscores the industry's reliance on predictive tools like PDX to stratify patients and accelerate the delivery of novel treatments to the clinic. Concurrently, the surging R&D expenditure in pharmaceutical and biotechnology sectors provides the necessary financial infrastructure to scale these resource-intensive platforms. Major industry players are aggressively increasing their investment in discovery pipelines to mitigate the risks of late-stage clinical failures, prioritizing high-fidelity models that offer superior translational validity. According to Fierce Biotech, March 2025, in the 'Top 10 pharma R&D budgets in 2024' report, AstraZeneca increased its research and development budget by 24% during the fiscal year to support its diverse oncology portfolio. Beyond corporate spending, foundational support remains vital for broader market stability; according to the National Cancer Institute, in 2025, the agency secured a total of $7.22 billion in federal funding to maintain its research initiatives. Collectively, these expanded financial resources enable the wider integration of patient-derived xenografts into standard drug development workflows.

Market Challenge

Despite this strong growth trajectory, the market faces a significant challenge due to the prohibitive costs and resource intensity associated with developing and maintaining these complex models. Unlike standard cell lines, PDX models demand specialized immunodeficient mice, advanced animal husbandry facilities, and continuous technical supervision, resulting in substantial operational overhead. This financial burden creates a significant barrier to entry for academic laboratories and smaller biopharmaceutical companies with limited capital, often compelling them to use less expensive, lower-fidelity preclinical tools and thus restricting broader market penetration. This constraint is further exacerbated by fluctuations in public sector support, such as a proposed 40% reduction in federal funding for the National Institutes of Health in 2025, which limits purchasing power and prioritizes cost-efficiency over model sophistication. Nevertheless, key trends are shaping the market's evolution, notably the widespread adoption of humanized immune system models. These next-generation platforms, engrafted with human hematopoietic stem cells or peripheral blood mononuclear cells, are redefining preclinical evaluation by enabling precise assessment of tumor-immune interactions and checkpoint inhibitor efficacy, driving portfolio expansions exemplified by Charles River Laboratories' new PBMC models. Concurrently, the integration of multi-omics profiling and AI analytics is transforming PDX utility from simple screening to deep biological characterization. By combining genomic, transcriptomic, and proteomic data with machine learning, developers can now identify predictive biomarkers and simulate virtual control groups, significantly enhancing translational reliability and creating lucrative revenue streams, a factor contributing to Champions Oncology's record quarterly revenue from its proprietary multi-omic dataset services and AI-driven platform usage.

Market Trends

The Widespread Adoption of Humanized Immune System Models is rapidly redefining the market as researchers prioritize preclinical tools capable of evaluating immuno-oncology therapies. Unlike traditional immunodeficient platforms, these next-generation models are engrafted with human hematopoietic stem cells or peripheral blood mononuclear cells, enabling the precise assessment of tumor-immune interactions and checkpoint inhibitor efficacy. This shift is driving significant portfolio expansions among major providers to meet the technical demands of long-term studies. According to Charles River Laboratories, April 2025, in the 'Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development' press release, the company expanded its commercial inventory by introducing two new PBMC models specifically engineered to delay graft-versus-host disease, thereby extending the therapeutic window for immune-mediated drug screening. Concurrently, the Integration of Multi-Omics Profiling and AI Analytics is transforming PDX utility from simple screening into deep biological characterization. By combining genomic, transcriptomic, and proteomic data with machine learning algorithms, developers can now identify predictive biomarkers and simulate virtual control groups, significantly enhancing translational reliability. This data-centric approach has become a lucrative revenue stream, as pharmaceutical clients seek actionable insights beyond standard tumor growth inhibition metrics. According to Investing.com, March 2025, in the 'Champions Oncology Q1 2025 earnings beat expectations' article, Champions Oncology achieved a record quarterly revenue of $17 million, a financial milestone largely attributed to the robust growth of its proprietary multi-omic dataset services and AI-driven platform usage.

Key Market Players

  • Charles River Laboratories Inc.
  • The Jackson Laboratory
  • Crown Bioscience,Inc.
  • Altogen Labs
  • Envigo RMS LLC
  • WuxiAppTec Co. Ltd
  • Oncodesign Services S.A.
  • Hera BioLabs Inc.
  • XenTech SAS
  • Abnova Corporation

Report Scope

In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Patient-Derived Xenograft Model Market, By Tumor Type

  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancer

Patient-Derived Xenograft Model Market, By Type

  • Mice
  • Rats

Patient-Derived Xenograft Model Market, By End-User

  • Inpatient Settings
  • Community Settings

Patient-Derived Xenograft Model Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.

Available Customizations:

Global Patient-Derived Xenograft Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Patient-Derived Xenograft Model Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer)
    • 5.2.2. By Type (Mice, Rats)
    • 5.2.3. By End-User (Inpatient Settings, Community Settings)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Patient-Derived Xenograft Model Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Tumor Type
    • 6.2.2. By Type
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Patient-Derived Xenograft Model Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Tumor Type
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Patient-Derived Xenograft Model Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Tumor Type
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Patient-Derived Xenograft Model Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Tumor Type
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End-User

7. Europe Patient-Derived Xenograft Model Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tumor Type
    • 7.2.2. By Type
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Patient-Derived Xenograft Model Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tumor Type
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Patient-Derived Xenograft Model Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tumor Type
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Patient-Derived Xenograft Model Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tumor Type
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Patient-Derived Xenograft Model Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Tumor Type
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Patient-Derived Xenograft Model Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Tumor Type
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End-User

8. Asia Pacific Patient-Derived Xenograft Model Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tumor Type
    • 8.2.2. By Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Patient-Derived Xenograft Model Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tumor Type
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Patient-Derived Xenograft Model Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tumor Type
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Patient-Derived Xenograft Model Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tumor Type
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Patient-Derived Xenograft Model Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Tumor Type
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Patient-Derived Xenograft Model Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Tumor Type
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Patient-Derived Xenograft Model Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tumor Type
    • 9.2.2. By Type
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Patient-Derived Xenograft Model Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tumor Type
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Patient-Derived Xenograft Model Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tumor Type
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Patient-Derived Xenograft Model Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tumor Type
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End-User

10. South America Patient-Derived Xenograft Model Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tumor Type
    • 10.2.2. By Type
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Patient-Derived Xenograft Model Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tumor Type
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Patient-Derived Xenograft Model Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tumor Type
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Patient-Derived Xenograft Model Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tumor Type
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Patient-Derived Xenograft Model Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Charles River Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. The Jackson Laboratory
  • 15.3. Crown Bioscience,Inc.
  • 15.4. Altogen Labs
  • 15.5. Envigo RMS LLC
  • 15.6. WuxiAppTec Co. Ltd
  • 15.7. Oncodesign Services S.A.
  • 15.8. Hera BioLabs Inc.
  • 15.9. XenTech SAS
  • 15.10. Abnova Corporation

16. Strategic Recommendations

17. About Us & Disclaimer